Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

Status: Enrolling_by_invitation
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a pilot open-label study to evaluate the feasibility of conducting a clinical trial using sublingual dexmedetomidine sublingual film to treat hyperadrenergic autonomic crises in patients with Familial Dysautonomia at home. The primary aims are to examine the feasibility of performing a clinical trial using dexmedetomidine at home to terminate autonomic crisis, and refine the interventions and assessments used to evaluate autonomic crisis termination.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Genetically confirmed diagnosis of Familial Dysautonomia.

• Evidence of autonomic crisis, previous treatment with IV dexmedetomidine without significant side effects, and registered medical data within the year preceding the study in our database.

• One or more autonomic crises during the last year.

• Age above 18 years.

• The patient has a responsible caretaker to communicate with the medical providers.

• Provision of signed and dated informed consent form from the patient and responsible caregiver.

• Able to state willingness to comply with all study procedures and availability for the duration of the study

• For males and females of reproductive potential: use condoms for contraception if sexually active.

Locations
United States
New York
NYU Langone Health
New York
Time Frame
Start Date: 2024-06-01
Completion Date: 2028-12
Participants
Target number of participants: 5
Treatments
Experimental: Sublingual dexmedetomidine
Participants will be administered two 60 micrograms sublingual films of IGLMI following start of an autonomic crises. The maximum amount for the study is four oral films of 60 micrograms in 24 hours, two at the beginning of the crises and if needed, two additional within two hours.
Sponsors
Leads: NYU Langone Health

This content was sourced from clinicaltrials.gov